Modern evolution theory suggests only the fittest will survive; in the business world, we know this to be fact. Find out what it takes to prepare your company for survival. Join this panel to hear survival tips from VC investors, and what they look for in a investment.
Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.
This event is typically sold out, therefore please register early to secure your spot!
- Peter McWilliams, Principal, Sanderling Ventures
- Bob Ward, Principal, Kaiser Permanente Ventures
- Anna Williamson, Business Development, Genentech Inc.
- Doug Fisher
, Principal, InterWest Partners
- Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP
• Regular Price: $45 before or on Sep. 16 | $55 on-site
• Partners' Network: $40 before or on Sep. 16 | $55 on-site
• BioCenter Members: Free (Please RSVP to Aurélie directly)
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Menlo Park, CA 94025-1015
Click here for Venue Directions»
Peter McWilliams, Principal, Sanderling Ventures
Peter McWilliams is a Principal with Sanderling Ventures and has more than 15 years experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Actimis Pharmaceuticals (sold to Boehringer Ingelheim), Trinity Biosystems, Artielle Immunotherapeutics, Harkness Pharmaceuticals, Calcimedica and Cylene Pharmaceuticals. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin. Prior to that he was an Associate with Booz.Allen & Hamilton in San Francisco where he focused on projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics, where he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.
Bob Ward, Principal, Kaiser Permanente Ventures
Bob was instrumental in establishing the Kaiser Permanente Venture Fund in 2000 and is responsible for managing the pipeline of new venture prospects, as well as leading investment evaluations and financing decisions. He is a manager or board observer for several portfolio companies and targets investments in imaging, lab/diagnostics, women's health and related therapeutics/devices. Prior to joining Kaiser Permanente in 1997, Bob pursued a career in banking at Wells Fargo and other financial institutions with responsibilities in treasury operations, performance planning/metrics, incentive compensation and finance training. He holds a MBA in Finance from the University of California at Berkeley and a Bachelor's Degree in Economics from the University of Washington. Bob has completed the executive management leadership program at the University of North Carolina and Venture Capital Institute graduate programs.
Anna Williamson, Business Development, Genentech Inc.
Anna Williamson is a Senior Manager in the Business Development Department at Genentech. Anna's responsibilities include sourcing, evaluating, and in-licensing research technologies and therapeutic products. While at Genentech, Anna has developed strategic collaborations with academic institutions and with companies such as Curis, Sangamo, Abbott and Symphogen. Prior to joining Genentech in 2004, Anna worked at the University of California Office of Technology Transfer where she was responsible for managing and out-licensing a portfolio of life sciences inventions from multiple UC campuses. Anna holds a BA in Natural Sciences and a Ph.D. in Neuroscience from the University of Cambridge, UK, and carried out post-doctoral research at the University of Colorado and the University of California, San Francisco.
Doug Fisher, Principal, InterWest Partners
Dr. Doug Fisher joined InterWest's life sciences team in 2009, focusing on biopharmaceutical and diagnostics investments. Prior to joining InterWest, Dr. Fisher was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including: Pearl Therapeutics, Access Closure, and GluMetrics. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area and consulted for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group where he developed product strategies in three new disease areas for Remicade. Dr. Fisher received an A.B. in economics with honors and distinction and a B.S. in biology with distinction from Stanford where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton where he graduated with honors as a Siebel Scholar and Palmer Scholar.
Facilitator: Scott Iyama, Corporate Attorney, Orrick, Herrington & Sutcliffe LLP
Scott Iyama, a corporate associate in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings and technology transactions.